skip to main content

Abstract 14509: Multicenter Randomized Controlled Trial Between Febuxostat and Allopurinol in Chronic Heart Failure Patients With Hyperuricemia

Suzuki, Satoshi ; Yoshihisa, Akiomi ; Sato, Akihiko ; Shimizu, Takeshi ; Sato, Takamasa ; Sakamoto, Nobuo ; Nakazato, Kazuhiko ; Tsuda, Tatsunori ; Tsuda, Akihiro ; Goto, Jun ; Ishibashi, Toshiyuki ; Konno, Ichiro ; Yamaguchi, Osamu ; Machii, Hirofumi ; Nozaki, Naoki ; Niizeki, Takeshi ; Miyamoto, Takuya ; Kubota, Isao ; Takeishi, Yasuchika

Circulation, 2017, Vol.136(Suppl_1 Suppl 1), pp.A14509-A14509 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Abstract 14509: Multicenter Randomized Controlled Trial Between Febuxostat and Allopurinol in Chronic Heart Failure Patients With Hyperuricemia
  • Author: Suzuki, Satoshi ; Yoshihisa, Akiomi ; Sato, Akihiko ; Shimizu, Takeshi ; Sato, Takamasa ; Sakamoto, Nobuo ; Nakazato, Kazuhiko ; Tsuda, Tatsunori ; Tsuda, Akihiro ; Goto, Jun ; Ishibashi, Toshiyuki ; Konno, Ichiro ; Yamaguchi, Osamu ; Machii, Hirofumi ; Nozaki, Naoki ; Niizeki, Takeshi ; Miyamoto, Takuya ; Kubota, Isao ; Takeishi, Yasuchika
  • Is Part Of: Circulation, 2017, Vol.136(Suppl_1 Suppl 1), pp.A14509-A14509
  • Description: Background: Hyperuricemia is known as a marker of oxidative stress and associated with adverse prognosis in patients with chronic heart failure (CHF). Febuxostat, a novel non-purine selective xanthine oxidase inhibitor, is currently available for hyperuricemia and chronic goat. The purpose of this study was to compare the effects of febuxostat and allopurinol, a purine analog and conventional xanthine oxidase inhibitor, on cardiac function and prognosis in CHF patients with hyperuricemia.Methods and Results: We enrolled 272 stable CHF patients with hyperuricemia (serum uric acid level >7.0 mg/dl), and randomly assigned to febuxostat (n=127) or allopurinol (n=135) treatment groups. There was no difference in baseline clinical characteristics including age, gender, blood pressure, blood tests, and echocardiographic data between the two groups. All subjects were followed up after enrollment. Two years after enrollment, uric acid levels in both groups were significantly decreased (8.47 ± 1.24 to 5.54 ± 1.27 mg/dl, P<0.01, in febuxostat group, 8.58 ± 1.20 to 5.26 ± 1.96 mg/dl, P<0.01, in allopurinol group), and there were no statistical significances in blood test data including levels of uric acid and plasma B-type natriuretic peptide, and echocardiographic data between the two groups. Kaplan-Meier survival curves demonstrated that the cardiac event-free rate including cardiovascular death and re-hospitalization due to worsening heart failure did not show significant difference between febuxostat and allopurinol groups (83.7% vs. 85.8%, P=0.386).Conclusion: The multicenter randomized trial demonstrated that febuxostat was effective to reduce uric acid level, and cardiac event-free rate was similar between febuxostat and allopurinol in CHF patients with hyperuricemia.
  • Identifier: ISSN: 0009-7322
  • Source: Copyright © 2013 Lippincott Williams & Wilkins. All rights reserved.

Searching Remote Databases, Please Wait